In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $179 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...
CLEO Diagnostics Ltd ( ($AU:COV) ) has issued an update. CLEO Diagnostics Ltd has applied to the ASX for quotation of 8,333,334 new fully paid ...
CEO Lishan Aklog highlighted a strong close to 2024 and an optimistic start to 2025, driven by advancements in EsoGuard sales channels, reimbursement milestones, and increased clinical evidence. He ...
CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...
Monday, Needham analysts raised the price target on Lucid (NASDAQ: LCID) Diagnostics Inc (NASDAQ: LUCD) shares to $3.00 from $2.50, while maintaining a Buy rating on the stock. The upgrade reflects an ...
Hosted on MSN
Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa
CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) ...
Vijaya Diagnostic’s (Vijaya) Q2FY26 performance was weaker than our expectations due to a slowdown in core markets of Hyderabad (+3% YoY). Pathology revenue grew at a modest pace of 5.1% YoY on a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback